Immune effectors required for the therapeutic activity of vorinostat

Oliver Kepp; Lorenzo Galluzzi; Guido Guido Kroemer

doi:10.4161/onci.27157

Related publications

Letter2020

Immunogenicity of cell death driven by immune effectors

Lorenzo Galluzzi, Giulia Petroni, Guido Guido Kroemer

Article2018

Immune effectors responsible for the elimination of hyperploid cancer cells

Fernando Aranda, Kariman Chaba, Norma Bloy, Pauline Garcia, Chloé Bordenave, Isabelle Martins, Gautier Stoll, Antoine Tesnière, Guido Guido Kroemer, Laura Senovilla

Article2009

TRAF6 Is Required for Generation of the B-1a B Cell Compartment as well as T Cell-Dependent and -Independent Humoral Immune Responses

Takashi Kobayashi, Tae Soo Kim, Anand Jacob, Matthew C. Walsh, Yuho Kadono, Ezequiel M. Fuentes‐Pananá, Tomoko Yoshioka, Akihiko Yoshimura, Masahiro Yamamoto, Tsuneyasu Kaisho, Akira Shizuo, John G. Monroe, Yongwon Choi

PLoS ONE

Article2022

Redox regulation of the immune response

Gerwyn Morris, Maria Gevezova, Victoria Sarafian, Michael Maes

Article2022

Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation

Minyu Wang, Soroor Hediyeh Zadeh, Angela Pizzolla, Kevin Thia, David Gyorki, Grant A. McArthur, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Miles C. Andrews, George Au‐Yeung, Ali Weppler, Shahneen Sandhu, Joseph A. Trapani, Melissa J. Davis, Paul J. Neeson